New cancer drug shows early promise, but trial cut short
NCT ID NCT06546553
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This early-stage study tested a new drug called PF-07826390, given alone or with another drug (sasanlimab), in people with advanced solid tumors like lung, kidney, and colorectal cancers. The goal was to check safety and find the right dose. Only 10 people took part, and the study was stopped early, so we have limited information.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- PF-07826390 (a bispecific antibody targeting LILRB1 and LILRB2)
- What this could lead to
- If it works, this could point toward a new treatment option for several advanced solid tumors, including lung, kidney, and colorectal cancers.
- What could go wrong
- This is a very early (Phase 1) and small (10 participants) trial that was terminated, so results are limited. The drug may not prove effective or safe in larger studies.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Beverly Hills Cancer Center
Beverly Hills, California, 90211, United States
-
Florida Cancer Specialists
Orlando, Florida, 32827, United States
-
Florida Cancer Specialists & Research Institute, LLC
Fort Myers, Florida, 33916, United States
-
START Midwest
Grand Rapids, Michigan, 49546, United States
-
START Mountain Region
West Valley City, Utah, 84119, United States
-
START San Antonio
San Antonio, Texas, 78229, United States
-
Sarah Cannon Research Institute at Florida Cancer Specialists
Orlando, Florida, 32827, United States
-
Virginia Cancer Specialists
Fairfax, Virginia, 22031, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new immunotherapy combo outsmart advanced lung cancer?
- A simple screening program could transform cancer aftercare
- Double attack on mutant KRAS: can two targeted drugs outsmart resistant cancers?
- Seeing the fight: new imaging tracer may reveal how immune cells attack lung cancer
- Could a bronchial wash detect lung cancer mutations faster?
- A new program aims to ease the 'Lost in Transition' struggle for cancer survivors